Moreover, shRNA-Ptbp1 treatment mitigated OGD-induced increases in PTBP1 and the astrocyte activation marker GFAP (Figure 3I-J), indicating the crucial role of PTBP1 in astrocyte dysfunction following ischemia. The gene discussed is GFAP; the disease is ischemia.